Trinity Biotech to Announce Q3 2024 Financial Results
Rhea-AI Summary
Trinity Biotech (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, will announce its Q3 2024 financial results on Friday, November 15, 2024. The company will host a conference call at 10:00 AM ET. Trinity Biotech focuses on developing diagnostic systems and has recently entered the wearable biosensor industry through the acquisition of Waveform Technologies Inc.'s biosensor assets. The company sells directly in the US, Germany, France, and the UK, while maintaining distribution partnerships across 75 countries worldwide.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TRIB declined 4.52%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET
DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the third quarter 2024 on Friday, November 15, 2024 and host a conference call at 10:00 AM ET.
Conference Call Dial-In & Webcast Information
| Date: | Friday, November 15, 2024 |
| Time: | 10:00 AM ET |
| United States: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: Webcast: Call me™: | 13750164 click here https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 |
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC |
| Louise Tallon | Eric Ribner | |
| (353)-1-2769800 | (1)-646-751-4363 | |
| E-mail: investorrelations@trinitybiotech.com |
FAQ
When will Trinity Biotech (TRIB) release Q3 2024 earnings?
What time is Trinity Biotech's (TRIB) Q3 2024 earnings call?
What are Trinity Biotech's (TRIB) main business segments?
In which countries does Trinity Biotech (TRIB) sell directly?
